Table 1.
Frequency listing of significant caudate nucleus dopaminergic, neocortical and PPN-thalamic cholinergic deficits in the total cohort of patients (left column) and cognitive severity subgroups based on global cognitive z-scores ranging from no or minimal (Z >−0.5) to more severe cognitive impairment (Z ≤ −2). Statistical significances for the distribution differences for each of the neurochemical deficits between the 5 cognitive sub-groups are listed in the right column.
| Neurochemical deficit | Z-score ranges | Statistical significance | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Z ≤ −2 cognitive sub-group (n=7) | Z in −1.5 to −2 range cognitive sub-group (n=11) | Z in −1.0 to −1.5 range cognitive sub-group (n=10) | Z in −0.5 to −1.0 range cognitive sub-group (n=26) | Z > −0.5 cognitive sub-group (n=88) | ||
| Caudate nucleus VMAT2 deficit (total group: 100/142, 70.4%) | n=5 (71.4%) | n=11 (100%) | n=5 (50%) | n=19 (73%) | n=45 (51.1%) | χ2=12.8, P=0.012* |
| Neocortical AChE deficit (total group: 46/143, 32.2%) | n=6 (85.7%) | n=8 (72.7%) | n=5 (50%) | n=5 (19.2%) | n=22 (24.7%) | χ2=23.20; P=0.0001* |
| PPN-thalamic AChE deficit (total group: 23/143, 16.8%) | n=2 (28.6%) | n=2 (18.2%) | n=3 (30.0%) | n=5 (19.2%) | n=11 (12.4%) | χ2=3.39; P=0.50 |
*
Significant variable after Holm-Bonferroni correction.